Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Yea he does own common although the preferreds weigh more. Last i saw it was a small amount, something like $25m shares worth at the time
This is good, just need chemport and nissin now to comment
Can anyone comment of non exclusive technology deal between inovio and oncs regarding immunopulse? Also read about neopulse phase 3 data which were halted by inovio in 2007? I know they transferred these along with the deal with oncs but would like to know what has oncs changed in neopulse in order for them to possibly alter outcomes compared to ino p3 failure. Appreciate any input.
Anyone have an idea of where this company should trade based on pure financials without conservatorship?
Am in with 43000 across multiple accounts
I agree, folks need to get in touch with afrochicken as one additional avenue to bring focus. Still cant believe mgmt still in a quiet period.
Zum, afrochicken on stocktwits needs data for his talk with citizen.org folks on fda amrn issue. They are willing and very interested in the story. Biobill asked that i let you know to get in contact with afrochicken
Afrochicken on stocktwits got in contact with citizen.orgs angela bradbery and dr sidney wolfe. Both are very interested in fda amrn story. He is asking for help on data for them...jl, biobil, speedrunner and all
Interesting point of view...i think perrigo is an alternative but gsk seems to make the most sense being that i would doubt they would disregard $1b in rev.
Excellent plan forward....mgmt should be defiant. Being meek will not help their case.
I think it was down a little from prior week, 6255 is what i think a member on stocktwits said but dont remember exactly.
Excellent last piece by sr, hes with amrn now apperently
START FROM BOTTOM
framus_morrigan Oct. 22 at 7:03 AM
@stephenrosenman @ckbike oh man, not a liberty to say who .... but you say who!
ReplyShareLike
stephenrosenman Oct. 22 at 6:26 AM
@ckbike The FDA panel webcast. Not at liberty to say who. Title is: Sr. VP Regulatory Affairs
ReplyShareLike
ckbike Oct. 22 at 6:06 AM
@stephenrosenman Who's this sr. regulatory figure and which webcast are you referencing?
ReplyShareLike
ckbike Oct. 22 at 6:06 AM
@stephenrosenman Who'
ReplyShareLike
stephenrosenman Oct. 22 at 6:05 AM
$AMRN Interesting conversation with sr. regulatory figure on webcast - says doctor comments and questions nullify 9-2 vote impact greatly
ReplyShareLike
stephenrosenman Oct. 22 at 1:34 PM
@YazzJr They have been talking to GSK and PFE for some time now. Not sure about AZn
ReplyShareLike
stephenrosenman Oct. 22 at 11:09 AM
@BESKST I'm not convinced that Anchor gets thumbs down. I have to believe with SPA and circus of Adcom that negotiation of label is in order
ReplyShareLike
Sorry just responded to you but replied to me....post below
If you go stock twits you and click on his main profile it will bring up all his messages. The longest and last ones he did he gave those odds prior to saying he was joining amarin. Can't read much into it but it's an alternative point of view. I can't confirm he's there but seeing a lot of people comment on it too. Additional points he mentioned was amrn was in talks with gsk and pfe for a while now....not too much with azn. Again take it with a grain of salt as these have been rumors for a while. I suggest you look for him on stock twits and read his comments.
Well sr has been a long time bull and he has access to a lot of the ideas expressed by some real great folks on several boards. They apperently brought him on as a consultant so maybe he can help them see a different angle. Don't know how much his input will help but nice to know they brought on someone who can an share alternate views.
For now he is still saying panel will be reviewed and assigns a 40/60% negative on anchor which is far better than 100% negative. Again maybe wishful thinking.....as they all say....when ws, public and comments are all negative...the opposite outcome could happen.....similar to the large positive confidence level going into adcom. Hoping for the best
Nevermind...he's been brought on by amarin as a consultant apperently...no longer posting on stock twits or SA.
For the few hopefuls...Other than gsk, mochida, elan.....I forgot about perrigo...vascepa is right up their alley in terms of product type and would be additive in a tax efficient manner. Perrigo finalized the deal with elan back in July. They are also a Large OTC company...not to say they would OTC vascepa yet.
Any truth to Steve Rosenman being hired by Amarin? Seeing it on Twitter
Agreed but you have to admit they were this negative during the cc as well so much to be expected in a sense. What it tells me is BP not quite interested at this point yet and they need to prepare and manage based on marine and off label sales. They will manage as a traditional company now without catalysts in the near term so make sense trim. If fda talks are negative we will have confirmation, hopefully, during the cc. Set back after set back has caused management to be overtly cautious now.
Yes waiting for the cc as well....movement today interesting but don't know if these are traders, hf traders or new actual long holders (maybe a blend). It's moving but not enough confirm real change in direction.....need a few more days to recover and stabilize. Can't wait to see positive 13f filings for new positions or for mgmt to buy their own shares in a meaningful way.
You should submit that along with new research to 60 minutes at 60m@cbsnews.com.....would be an interesting topic of discussion.
I was thinking the same thing....
Excellent piece will be forwarding it on to some other pcps.
Got it thank you as usual...
Oh ok, why would he say an anonymous amrn rep gave it to him? If you gave it, he should say you did. Any possibility you can post it for us on the board?
Doc not found...error 4
They should really pr this info as public needs to know granted fda hasnt crl them yet
Honestly i agree but we need someone good with BP background to come in at the same time or stock price will languish. Board needs to discuss this...maybe we get some pr end of today or early tomorrow.....they need to communicate.
Ok sounds good....thank you for your guidance....still would've been nice for amrn mgmt to have plan b in place considering they wrote about it in their 10q.
Bio, do you know afrochicken on stocktwit? His recent post about receiving the fda day 74 letter from an amrn rep? Sounds like actual communication from fda which may have contributed to blindsided amrn mgmt during adcom. Any chance you could get him to send it to you? May help
Stock twits member afrochicken said he got an anonymous letter from an amrn rep called a day 74 letter from fda? Not sure what that is. Anyway he is now saying the letter clearly explains why amarin was not prepared for adcom on anchor. May have been misdirection from fda. Anyone know who he is so we can get a copy?
I agree.....just interested in seeing actual company pr.
Oncs board....long time observer and investor...looking forward to success in this much un noticed company.
Excellent bio! Amarin needs to give you some of their .001 cent options to execute for your work and support.
Yes it does so surprising that no pr has been issued. Again I don't know what was said or not said by bruno, what I do know is that if it material, it should be disclosed via pr because public needs to know.
Ir should release a pr on this very topic because it should be public information and not available on this board only. If something went on that didnt follow protocol, it should be wit their legal team and not disseminated yet to the public while they prepare. Biotechwill tried to get an interview and they declined recently so not sure how comments were made. If true, a pr is needed as it should be public information.
Interesting....i was under impression they get briefing docs a little earlier than public does to prepare. Can anyone clarify this?
Thanks go seek